2 results
Approved WMOCompleted
To provide idelalisib, a marketed PI3K* inhibitor, in lieu of GS-9820, an investigational second generation PI3K* inhibitor, to subjects receiving GS-9820 in Study GS-US-315-0102 at the time of study closure.
Approved WMOCompleted
Primary: To determine the feasibility of measuring muscle strength at home with the fixed dynamometerSecondary: Determining the sensitivity of the fixed dynamometer to detect changes in disease progression in ALS during home measurement